Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in

Status Completed

Clinical Trial Summary

Open randomized therapeutic study to assess the efficacy of Xarelto 15mg/day in the recurrence of thromboembolic event compared to an untreated group in patients with chronic portal vein thrombosis without high risk thrombophilia.

Clinical Trial Description

Chronic portal vein thrombosis (PVT) is a rare disease, affecting young patients, characterized by permanent obstruction of the portal vein trunk causing portal hypertension. In 60-70% of cases it is related to high risk, moderate or mild prothrombotic risk factors. Accordingly, there are 2 types of complications from PVT :(i) gastrointestinal haemorrhage related to portal hypertension; and (ii) recurrent thrombosis. Recurrent thrombosis its most dreaded complication as it may lead to intestinal infarction with a related mortality of 20-60% and a high risk of intestinal insufficiency. Gastrointestinal haemorrhage related to portal hypertension occurs in 20% patients/year. It is less frequent in patients treated with medical or endoscopic prophylaxis for variceal bleeding. Retrospective data shows that anticoagulation does not worsen the prognosis, and may conversely improve it. Thus, in patients at risk for gastrointestinal bleeding due to portal hypertension and a mild or moderate risk of recurrent thrombosis, the benefit-risk ratio of anticoagulation therapy is unclear. The aim of this open randomised trial is to assess the efficacy of Xarelto 15mg/day, a new oral factor Xa inhibitor, in the recurrence of thromboembolic event and the risk of major bleeding compared to an untreated group in patients with chronic portal vein thrombosis without high risk thrombophilia. The hypothesis of the trial is that treatment with Xarelto® would reduce the risk of recurrence of acute deep vein thrombosis (DVT) regardless location, with limited increase in the risk of hemorrhage in patients with chronic portal thrombosis and no high-risk factors for thrombosis recurrence This is a national, multicentric, interventional study. 17 french centers already agreed to participate. 296 patients will be included on a 3 years period with 2 to 4 years treatment period. All data will be collected after informed consent will be obtained. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02555111
Study type	Interventional
Source	Assistance Publique - Hôpitaux de Paris
Contact
Status	Completed
Phase	Phase 3
Start date	September 2015
Completion date	February 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05003843` - BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis	N/A
Recruiting	`NCT03937947` - Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
Withdrawn	`NCT04136561` - Novel Strategy to Encourage Early Removal of Central Venous Catheters	N/A
Completed	`NCT03420625` - Blood Flow Stimulation in the Lower Limbs by Application of Different External Devices	N/A
Recruiting	`NCT02507180` - Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
Completed	`NCT01975090` - The SENTRY Clinical Study	N/A
Terminated	`NCT02469376` - Evaluation of a New Imagingtechnologie for Thrombosis	Phase 1
Completed	`NCT02037607` - Incidence of Venous Thromboembolism in Children Undergoing Elective Neurosurgical Procedures	N/A
Not yet recruiting	`NCT01357941` - Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)	N/A
Completed	`NCT00771303` - Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
Completed	`NCT00773448` - Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism	N/A
Completed	`NCT00720915` - D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months	N/A
Completed	`NCT00244725` - Odiparcil For The Prevention Of Venous Thromboembolism	Phase 2
Completed	`NCT00264277` - D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism	Phase 4
Completed	`NCT00365950` - 3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE	Phase 4
Completed	`NCT00182403` - Fixed Dose Heparin Study	Phase 3
Completed	`NCT03682419` - Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL)	N/A
Not yet recruiting	`NCT04981327` - The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis	Phase 3
Recruiting	`NCT03240120` - A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism	Phase 3
Completed	`NCT03124654` - Development of a Questionnaire to Assess Patient Knowledge About Non-vitamin K Anticoagulants (NOAC)	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis. — RIPORT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms